1.Biological Monitoring.
Yeungnam University Journal of Medicine 1995;12(1):21-31
No abstract available.
Environmental Monitoring*
2.Analytical solution of linear multi-compartment models with non-zero initial condition and its implementation with R
David Z D'ARGENIO ; Kyun Seop BAE
Translational and Clinical Pharmacology 2019;27(2):43-51
The analytical solution for multi-compartment models with a non-zero initial condition is complex because of the inter-compartmental transfer. An elegant solution and its implementation in the ‘wnl' R package can be useful in solving examples of textbooks and developing software of therapeutic drug monitoring, pharmacokinetic simulation, and parameter estimation. This solution uses Laplace transformation, convolution, matrix inversion, and the fact that the general solution of an inhomogeneous ordinary differential equation is the sum of a homogenous and a particular solution, together.
Drug Monitoring
3.Microsurgical Removal Technique of the Spinal Intramedullary Glomus AVM with Intraoperative Monitoring of the Somatosensory-Evoked Potential(SEP).
Joon Ki KANG ; Chun Kun PARK ; Moon Chan KIM ; Jin Un SONG ; Young Bae KIM
Journal of Korean Neurosurgical Society 1984;13(4):715-723
The surgical treatment of spinal arteriovenous malformations has been improved markedly during the last several years by use of the operating microscope and microsurgical instrumentations. The possibility of total removal has been viewed pessimistically. However, total extirpation of spinal intramedullary arteriovenous malformation(AVM) can be possible by use of intraoperative monitoring of the somatosensory evoked potentials(SEPs). Authors report a case of spinal intramedullary glomus AVM which was successfully removed with intraoperative monitoring of the SEPs and discuss surgical management. Intraoperative monitoring of the SEPs to determine the safety of removing of the spinal intramedullary AVM is stressed.
Arteriovenous Malformations
;
Monitoring, Intraoperative*
4.The Clinical Study on the Predictability of Time from Toxic Level to Therapeutic Concentration on Phenytoin Toxicity.
Hyeon Mi PARK ; Young Ju LEE ; Hee Tae KIM ; Seung Hyun KIM ; Ju Han KIM ; Myung Ho KIM ; Tae Soon MOON ; Dong Jin SHIN ; In Jin JANG ; Sang Gu SHIN
Journal of the Korean Neurological Association 1996;14(2):440-447
It is important to predict time to reach therapeutic concentration in phenytoin toxicity. In tradition, frequent drug monitoring is inevitable until the therapeutic serum level is reached. A method of estimating Vmax and Vd of phenytoin with application to estimating time to reach therapeutic concentration of phenytoin is described. We evaluated the usefulness of that method in twelve patients with phenytoin toxicity whose initial levels ranging from 27.7 to 74.0 ug/ml. We compaired the observed time defined as the time of returning from the initial toxic level to the optimum therapeutic level by serial measurement of serum concentration with the calculated time by using the modified Michaelis-Menten equation (Km x In (C1/C2) +Cl-C2=Vmax/vd x T). We determined individual patient's Vmax (maximal metabolic rate of concentration), Vd(volume of distribution of concentration), and Km(constants of Michaelis-Menten equation) for phenytoin, using data obtained from two consecutive serum concentration and known value of Km in Korean. And then, we calculated the decline time of phenytoin. The calculated decline time did not differ significantly from observed decline time (P=0.830). It is possible to predict the time to the therapeutic range and to reduce the unnecessarily frequent drug monitoring.
Drug Monitoring
;
Humans
;
Phenytoin*
5.Evaluation of Vitros 950 for Quantitative Analysis of Digoxin and Theophylline.
Jong Phil KIM ; Min KIM ; Myoung YUN ; Chang Jae LEE ; Jong Hee SHIN ; Soon Pal SUH ; Dong Wook RYANG
Korean Journal of Clinical Pathology 1999;19(4):409-413
BACKGROUND: We evaluated the Vitros 950 (Johnson & Johnson Clinical Diagnostics, Inc., NY, USA) in the measurement of digoxin and theophylline levels and compared its results to those of the TDxFLx II (Abbott Laboratories, IL, USA) used for therapeutic drug monitoring (TDM) world-widely in order to assess the utility of the Vitros 950 as a TDM instrument. METHODS: From June 1997 to August 1997, 125 and 135 candidates for TDM were randomly chosen to measure digoxin and theophylline, respectively, using the Vitros 950 and TDxFLx II. The relationship between its results and those of TDxFLx II were determined. The within-run and between-run precisions of the Vitros 950 were determined using two controls (Vitros Performance Verifier I and II; J & J Clinical Diagnostics, Inc., NY, USA). The high-concentration control (Vitros Performance Verifier II) was diluted in Vitros 7% BSA to 5 dilutions. And linearity for quantitative analysis of digoxin and theophylline were determined. RESULTS: The coefficients of variation (CV) for the within-run of the Vitro 950 were 0.8% - 4.4%. And the CV for between-run precision of the Vitro 950 were 1.7% - 12.3%. The linearity of digoxin and theophylline were relatively good. The correlations (r) of digoxin and theophylline levels with those determined by the Abbott TDxFLx II were 0.95 and 0.93, respectively (P <0.001). CONCLUSIONS: The recently developed dry slide method of the Vitros 950 proves to good precision and linearity for quantitative analysis of digoxin and theophylline. Its results correlate well with those of the TDxFLx II. The Vitros 950 does not require an elaborate preparatory protocol for the sample, and is easy to use and maintain.So it is considered a highly feasible instrument for stat test.
Digoxin*
;
Drug Monitoring
;
Theophylline*
6.Therapeutic Drug Monitoring of Mycophenolic Acid.
Journal of Laboratory Medicine and Quality Assurance 2008;30(2):243-247
No abstract available.
Drug Monitoring
;
Mycophenolic Acid
7.Therapeutic Drug Monitoring of Tacrolimus and Sirolimus.
Sail CHUN ; Woochang LEE ; Won Ki MIN
Journal of Laboratory Medicine and Quality Assurance 2008;30(2):241-242
No abstract available.
Drug Monitoring
;
Sirolimus
;
Tacrolimus
8.The Therapeutic Drug Monitoring Consultation on Cyclosporine.
Journal of Laboratory Medicine and Quality Assurance 2008;30(2):237-239
No abstract available.
Cyclosporine
;
Drug Monitoring
10.Antimalarial drug quality monitoring in 2007
Hai Ngoc Trinh ; Thuan Khanh Le ; Tuy Quoc Tran ; Nhu Van Truong ; Nieu Thi Nguyen
Journal of Malaria and parasite diseases Control 2003;0(1):90-95
Background: Monitoring antimalarial drug quality should be conducted regularly in locals to enhance the effect of treatment for malaria \r\n', u'Objective: to study and analyze antimalarial drug quality\r\n', u'Subjects and methods: The study was carried out in 2007 for 5 provinces supported by the Global Fund: Ha Giang, Dien Bien, Thanh Hoa, Quang Tri and Gia Lai. Material were malaria drugs: artesunat, chloroquin, quinine, mefloquin, fansidar\u2026etc\r\n', u'Results and conclusion: The strict supervision on the anti-malarial drug quality by the National Malaria Control Program was very good and no substandard antimalarial drugs were detected. Evaluation of antimalarial drug quality and control was made for finding out the counterfeit drugs through sentinel sites in both private and public sectors. A total of 268 samples were collected, of which 13 samples were found substandard drugs (8 samples collected in private and 5 samples in public sectors). No counterfeit drugs were found. \r\n', u'
Antimalarial drug
;
quality
;
monitoring